侯宝玉

【摘 要】目的：讨论脾氨肽联合孟鲁司特钠治疗小儿咳嗽变异性哮喘患者的临床效果。方法：选择2020年1月至2021年1月该院接诊的小儿咳嗽变异性哮喘患者100例，依据随机数字表法分成两组，各50例。两组患者均开展传统治疗，对照组在常规计划方案上加用孟鲁司特钠治疗，观察组在对照组基础上加用脾氨肽治疗。对比两组患者临床治疗效果及副作用发生率。结果：治疗后，观察组治疗总有效率为96.00%，显著大于对照组的76.00%，差别有统计学意义（P<0.05）；观察组副作用发生率为4%，对照组为18%，两组对比差别有统计学意义。结论：孟鲁司特钠联合脾氨肽治疗小儿咳嗽变异性哮喘成效显著，不容易增加副作用，安全系数高，非常值得临床应用推广。

【关键词】小儿咳嗽变异性哮喘；孟鲁司特钠；脾氨肽；临床效果

Clinical observation of spleen Aminopeptide combined with montelukast sodium in the treatment of cough variant asthma in children

Hou Baoyu

Department of Pediatrics， Dongming people’s Hospital， Shandong Heze 274500，China

【Abstract】Objective： To discuss the clinical effect of spleen ammonia peptide combined with montelukast sodium in the treatment of children with cough variant asthma.Methods： The 100 pediatric cough variant asthma patients received from January 2020 to January 2021 were selected and divided into two groups with 50 cases in each group according to the randomized digital table.The two groups of patients performed traditional treatment， the control group was treated with montelukast sodium therapy on the basis of routine planning scheme， and the observed group was treated with spleen Aminopeptide on the basis of the control group.Clinical treatment effect and incidence of side effects were compared in the two patients.Results： After treatment， the total effective rate of the observation group was 96.00%， which was significantly greater than 76.00% of the control group， significant（P<0.05）；The incidence of side effects in the observation group was 4%， and18%in the control group， and significant difference.Conclusion： Monluast sodium combined with spleen ammonia peptideis effective in the treatment ofcough variant asthma in children， which is not easy to increase side effects and high safety factor， which is very worthy of clinical application.

【Key？Words】Pediatric cough variant asthma； Montelukast Sodium； Splenic aminopepin； Clinical effect

小兒咳嗽变异性哮喘属于哮喘病范围，常发于6岁以内儿童，且近些年病发率慢慢提高。儿童呼吸道及内脏器官发育不完善、抵抗力差，此病易复发、容易久治不愈，乃至恶变为慢性支气管炎，危害患者身体健康及生活品质。

现阶段，临床医学上大多数选用孟鲁司特钠治疗小儿咳嗽变异性哮喘。但药品抗药性慢慢提高，临床医学效果不佳，已不能满足小儿咳嗽变异性哮喘的诊治规定，寻找合理的用药治疗方案至关重要。有分析强调，脾氨肽能调整人体免疫，提高患者的免疫功能，从而合理控制病菌、感染等，减少临床抗药性，提高治疗效果。据此，本研究讨论脾氨肽联合孟鲁司特钠治疗小儿咳嗽变异性哮喘的临床效果，现报导如下。……